Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EU needs to modify existing guidance for nanotech risk assessment

This article was originally published in Clinica

Executive Summary

Modifications to the existing EU technical guidance for the risk assessment of chemicals will be necessary for nanomaterials, including those used in medical technology. That is the view of the EU's Scientific Committee on Emerging and Newly Identified Health Risks (SCENIHR), which has just published a scientific opinion on the appropriateness of the EU Technical Guidance Documents for chemicals in regard to nanomaterials.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT049427

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel